Company: CMND
Filing Date: 2025-03-13
Form Type: POS AM
Source: 0001213900-25-023708
Chunk: 37

Company: Clearmind Medicine Inc.
Filing Date: 2025-03-13
Form: POS AM
Chunk 37
---
 There
can be no assurance that U.S. investors will be able to enforce against us, members of our Board, officers or certain experts named herein
who are residents of Canada or other countries outside the United States, any judgments in civil and commercial matters, including judgments
under the federal securities laws. There is uncertainty with respect to whether a Canadian court would take jurisdiction on a matter
of liability predicated solely upon U.S. federal securities laws, and uncertainty with respect to whether a Canadian court would enforce
a foreign judgment on liabilities predicated upon the securities laws of the United States.

<div align='center'>WHERE YOU CAN FIND MORE INFORMATION</div>

We have filed with the SEC a registration statement
on Form F-1 under the Securities Act relating to this offering of our Common Shares. This prospectus does not contain all of the
information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this
prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents of any contract,
agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions
of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document
itself for a complete description of its terms.

Our SEC filings are available to the public at
the SEC’s website at http://www.sec.gov. Upon completion of this offering, we will be subject to the information reporting
requirements of the Exchange Act that are applicable to foreign private issuers, and under those requirements will file reports with
the SEC. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of
proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery
provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file reports
and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange
Act.

We maintain a corporate website at https://www.clearmindmedicine.com/.
Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus.

<div align='center'>26

INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>

The SEC allows us to incorporate by reference
information